Arkolith/Insider Trading/LABP/Form 4

Garabedian Christopher Nishan

DirectorLandos Biopharma, Inc. (LABP) · full profile →Form 4 · filed May 23, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
0 non-derivative · 3 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 23, 2024Disposed to issuer(D)2K——0
May 23, 2024Disposed to issuer(D)2K——0
May 23, 2024Disposed to issuer(D)2K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-014336) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML